Evaluation of whole blood point-of-care placental growth factor testing for prediction of adverse maternal and perinatal outcomes: a prospective observational cohort study in Sierra Leone

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Objectives

Pre-eclampsia is a major cause of maternal death. Placental growth factor (PlGF) testing improves time-to-diagnosis and outcomes. We evaluated two novel, whole blood, point-of-care (POC) PlGF tests (RONIA TM and Lepzi® Quanti PlGF) in a low-resource setting, for prediction of adverse outcomes.

Study Design

A prospective observational cohort study in hypertensive pregnant women, 24–36 +6 weeks’ gestation, at a tertiary maternity hospital in Sierra Leone.

Methods

Eligible, consented women underwent RONIA TM and/or Lepzi® Quanti PLGF testing; results were concealed. Optimal rule-out and rule-in thresholds were determined for prediction of predefined maternal (maternal death, eclampsia) and perinatal (stillbirth, termination pre-viability, neonatal death before discharge) composite outcomes. Sensitivity, specificity, negative (NPV) and positive predictive values were determined.

Results

Analysis was performed on women with complete outcomes: RONIA TM n=488 and Lepzi® Quanti PlGF n=140. Optimal thresholds were <60pg/mL or <90pg/mL (rule-out) and <20pg/mL or <12pg/mL (rule-in) for RONIA TM and Lepzi® Quanti PlGF respectively. For tests performed <34 weeks’ gestation, RONIA TM PlGF <60pg/mL had high sensitivity, 94.9% (95%CI 82.7-99.4%) and NPV, 94.6% (95%CI 81.8-99.3%) for maternal outcomes, with sensitivity, 100% (95%CI 95.8-100.0%) and NPV, 100% (95%CI 90.5-100%) for the perinatal composite. Lepzi® Quanti PlGF < 90pg/mL had 100% sensitivity and NPV for all predefined maternal and neonatal outcomes. Performance reduced slightly at later gestations.

Conclusions

Whole blood POC-PlGF measurement demonstrates accurate rule-out performance of two novel devices for serious outcomes, with potential for individualised risk stratification in low-resource settings.

Article activity feed